The FDA has "repeatedly stated that effectiveness against transmission remains unproven," the trio write, noting that the agency’s website maintains: "the scientific community does not yet know if Comirnaty will reduce such transmission."
"Our meta-analysis highlights a link between SARS-CoV-2 vaccination and new onset or worsening of inflammatory and autoimmune skin diseases," the study authors write.